Andrea Cox is currently a Professor of Medicine and Oncology at The Johns Hopkins
University School of Medicine in Baltimore.  She earned her Ph.D. studying T cell
immunology at The University of Virginia. She subsequently completed an M.D. and
then Internal Medicine and Infectious Disease training at Johns Hopkins. As a member of
the Viral Hepatitis Center in the Division of Infectious Diseases, she specializes in the
treatment of patients with hepatitis virus infections and HIV. Her laboratory investigates
human immune responses to hepatitis C virus (HCV), hepatitis B virus (HBV), SARS-
CoV-2, and HIV, including mechanisms through which these viral infections stimulate
and evade immune responses, and in HCV vaccine development. She is the PI of a U19
investigating mechanisms of spontaneous and vaccine mediated hepatitis C virus control
to direct rational development of a novel HCV vaccine and is the co-director of the Johns
Hopkins SARS-CoV-2 Pathogenesis and Immunity Center. She was the principal
investigator on the first prophylactic HCV vaccine trial implemented in an at-risk
population, and is the lead immunologist on an ACTG trial of HBV vaccines in people
living with HIV. She is a member of the American Society for Clinical Investigation and
Alpha Omega Alpha Honor Society.